Evaluation of effects of Ra-223 chloride therapy for bone metastasis of prostate cancer by quantitative bone SPECT/CT

Evaluation of effects of Ra-223 chloride therapy for bone metastasis of prostate cancer by quantitative bone SPECT/CT - Evaluation of Ra-223 therapy for bone metastasis of prostate cancer by quantitative bone SPECT/CT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024201

Enrollment

Registered

2016-09-28

Start date

2016-09-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone metastasis of castration resistant prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: ? A patient with bone metastasis of castration resistant prostate cancer ? A patient without known massive metastatic lesion except bone metastasis ? A patient who is done or planned a quantitative bone SPECT/CT within 30 days before the initial administration of Ra-233 therapy ? A patient who consents to this study on the document form

Exclusion criteria

Exclusion criteria: ? A patient with worse bone marrow dysfunction more than WHO grade III ? A patient with any massive metastatic lesion except bone, such as brain, lung or liver ? A patient who received radiation therapy or surgical therapy within 30 days, or who plans either therapy ? A patient who deny the prosecution of this study in the middle of the study

Design outcomes

Primary

Measure	Time frame
Relationship between bone SUV or bone scan index (BSI) and bone pain evaluation score (VAS score)	—

Countries

Japan

Contacts

Public ContactIchiei Kuji

Saitama Medical University International Medical Center Clinical test assistant center

chikens@saitama-med.ac.jp042-984-4523

Outcome results